Conclusions
REMISSION
Based on our analysis of upadacitinib maintenance trial data, the stringent mucosal healing endpoints, HEMI, and HEMR were both clinically relevant with HEMR being associated with the greatest likelihood of improvement in long-term clinical and patient-reported outcomes. Early HEMI and HEMR are independent predictors of later remission and improved quality of life. Data on achieving the endoscopic remission and histologic remission endpoints and their benefit on long-term outcomes in upadacitinib-treated patients support HEMI and HEMR as desirable treatment goals in UC.